$22,268$17,11330.1%Sales and marketing
21,90619,47112.5%Total selling, general and administrative expense
$59,235$46,87726.4%General and administrative. The increase in general and administrative expenses for the quarter ended March 31, 2011, compared to the same quarter in 2010, corresponded principally to increases in head count and travel expenses, as a result of the growth of our business and increase in business development activities.
Sales and marketing. The increase in sales and marketing expenses for the quarter ended March 31, 2011, compared to the quarter ended March 31, 2010, was attributable to an increase in salaries as we recently expanded our sales force in the fourth quarter of 2010.
Share-based compensation. The increase in share-based compensation for the quarter ended March 31, 2011, compared to the same quarter in 2010, reflects the increase in share-based compensation recognized in connection with our share tracking awards plans.
2011-2013 Revenue GuidanceWe currently expect full-year revenues from our three commercial products (Remodulin, Tyvaso and Adcirca) to fall within a range of 5% above or below $750 million in 2011, $875 million in 2012 and $1 billion in 2013.
These expectations do not include projected revenues from oral treprostinil or our other investigative products. Guidance for 2012 and 2013 is subject to greater variability and uncertainty than the guidance for 2011. As a result, we anticipate reaffirming or updating all of these expectations on an annual basis when we present full-year results, and reaffirming or updating current-year guidance when we present our quarterly results.
Earnings Before Non-Cash ChargesEarnings before non-cash charges is defined as net income, adjusted for the following non-cash charges, as applicable: (1) interest; (2) income tax
|SOURCE United Therapeutics Corporation|
Copyright©2010 PR Newswire.
All rights reserved